<DOC>
	<DOCNO>NCT01559077</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability , pharmacokinetics pharmacodynamics single dose ALN-TTR02 healthy volunteer subject .</brief_summary>
	<brief_title>Trial Evaluate Safety , Tolerability , Parmacokinetics ALN-TTR02 Healthy Volunteer Subjects</brief_title>
	<detailed_description />
	<mesh_term>Amyloidosis</mesh_term>
	<criteria>Body mass index must 18.0 kg/m2 â‰¤ 31.5 kg/m2 ; Nonsmokers least 3 month precede screening ; Females subject must nonchildbearing potential e.g. , postmenopausal premenopausal surgical sterilization ; Males agree use appropriate contraception ; Medical history must verify either personal physician medical practitioner appropriate ; Willing give write informed consent willing comply study requirement . Known hepatitis B surface antigen ( HBsAg ) , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) human immunodeficiency virus ( HIV ) infection Multiple drug allergy know sensitivity oligonucleotide History drug abuse and/or alcohol abuse Receiving investigational agent within 3 month prior study drug administration Subjects safety laboratory test result deem clinical significant Investigator ; Received prescription drug within 4 week first dose Subjects donate 500 mL blood within 3 month prior ALNPCS02 placebo administration ; Subjects use prescription drug within 4 week first dose Considered unfit study Principal Investigator Employee family member sponsor clinical study site personnel</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>ATTR</keyword>
</DOC>